Results 171 to 180 of about 3,269,321 (296)

Mutual Information-based Prognostic Biomarker Discovery in Cancer Genomics: Conceptual Framework and Representative Applications of MI-POG. [PDF]

Cancer Genomics Proteomics
Akimoto K, Tamori S, Sato K.
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

ARMSTRONG DATABASES FOR FUNCTIONAL AND INCLUSION DEPENDENCIES

, 1983
An Armstrong database is a database that obeys precisely a given set of sentences (and their logical consequences) and no other sentences of a given type.
Ronald Fagin, Moshe Y. Vardi
core  

Patient-Derived Organoid-Based CRISPR Screens in Cancer Research: Applications, Advances, and Challenges. [PDF]

Cancer Med
du Plessis J, Omar A.
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

A dependency map enhanced with next-generation 3D cancer models. [PDF]

Nature
Neiswender JV, Maffa S, Brenan L, ElHarouni D, Yun Y, Boyle I, Wienand K, Inam H, Bertea T, Anderson A, Wong M, Enriquez M, Lenz E, Villafranca B, Shanks N, Hager M, Lloyd N, Shadmany H, Wie SJ, Liang H, Yunghans K, Zhang X, Golden L, Harris H, Day S, Montgomery P, Stokes S, Giglio RM, Hajal C, Whittle JR, Garcia G, Mills CE, Touat M, Pelton K, Li H, Prabhakar PS, Herter S, Kamrat ZH, Gui D, Dilly J, Wong CK, Guo JA, Pal S, Baidi Y, Johnston R, Brown DD, Bhatia S, Winter PS, Raghavan S, Beroukhim R, Colas E, Spector DL, Bass AJ, Sorger PK, Chen Y, Hill SJ, Oesterreich S, Lee AV, Beltran H, Boehm JS, Tseng YY, Root DE, Hahn WC, Aguirre AJ, Campbell CD, Ligon KL, Dempster JM, Shibue T, Vazquez F.   +68 more
europepmc   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

Propagation Mechanisms of Security Risks in Public Data Circulation via Inter-Risk Dependencies: A DSM-Based Network Analysis. [PDF]

Risk Anal
Wang N, Li Y, Mikkonen T, Li W, Cong F.
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Systematic multivariate analysis of chromatin complex dependencies reveals Set1C/COMPASS as a melanoma-enriched epigenetic vulnerability. [PDF]

PLoS Comput Biol
Camacho LQ, Fallahi-Sichani M.
europepmc   +1 more source